Myriad Acquires Sividon Diagnostics

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has acquired Sividon Diagnostics, a leading breast cancer prognostic company, for €35 million upfront with the potential for €15 million in additional performance-based milestones.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news